Please provide your email address to receive an email when new articles are posted on . The researchers added that, “subsequently, [biosimilar adalimumab] effectiveness and safety were proved in two ...

The U.S. Food and Drug Administration (FDA) approved Novartis' (NYSE:NVS) citrate-free high-concentration formulation (HCF) of Hyrimoz, a biosimilar to AbbVie's (NYSE:ABBV) blockbuster drug Humira.

Basel, November 21, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz ® (adalimumab) citrate-free high concentration formulation (HCF; 100 ...

Basel, July 21, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics ...

The FDA has approved the third biosimilar to adalimumab, adalimumab-adaz, for all eligible indications of the biologic product, according to a company press release. Hyrimoz (adalimumab-adaz, Sandoz), ...

(Reuters) -Cigna Group's Express Scripts pharmacy benefits unit will add three biosimilar versions of AbbVie's blockbuster arthritis treatment Humira to its list of preferred drugs, the company said ...

The FDA's approval was supported by data from analytical, preclinical, and clinical research showing that Hyrimoz matched the reference product's safety, efficacy, and quality. Hyrimoz, a tumor ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

The US Food and Drug Administration has approved a citrate-free, 100 mg/mL formulation of the biosimilar adalimumab-adaz (Hyrimoz), according to a statement from manufacturer Sandoz. Sandoz said that ...

CVS Health (NYSE:CVS) has launched a new subsidiary dedicated to marketing biosimilars in the US, with Sandoz’s version of the top-selling medication Humira as its first product. The healthcare ...